Mountain View, Calif.-based Ceribell is developing a Rapid Response EEG system, which consists of a disposable headband and mobile recorder and is intended for the rapid diagnosis of patients with suspicion of seizure.
Data is transmitted through a HIPAA compliant cloud portal for specialist review. The system can be set up quickly by healthcare providers to allow for bedside triage through the use of the company’s Brain Stethoscope, which converts EEG signals to sound, Ceribell said.
“We are extremely pleased to have such a strong and diverse syndicate with leaders from pharma, medical device, and best-in-class healthcare investors. We started our mission because we saw how seizure patients in the ICU and ED in even the best US hospitals suffered from delayed treatment due to lack of EEG. Some suffered major neurological deficits while others simply didn’t make it. We are excited to see visionary pioneer health care practitioners already adopting our technology and transforming their EEG capability. We are excited to have the funds to reach more hospitals and help them significantly improve patient care,” Ceribell CEO Jane Chao said in a press release.
The round was also joined by the newly invested Optimas Capital Partners Fund, The Rise Fund and included participation from UCB and LivaNova.
“Ceribell is transforming how we monitor and diagnose seizures in ICU and ED patients that are at highest risk for poor outcomes. Early and accurate treatment of seizure patients is critical for patients’ outcomes, and Ceribell provides the tools to enable early and accurate diagnosis. We believe that Ceribell’s groundbreaking innovations will not only save more lives, but also significantly improve the quality of life for patients,” Optimas chief investment officer Yongzhi Jiang said in a prepared statement.